ZIKV DNA vaccine: Phase I started

NIH’s National Institute of Allergy and Infectious Diseases (NIAID) began the open-label, U.S. Phase I VRC 319 trial to evaluate 4 regimens of intramuscular ZIKV DNA vaccine in up to 80 healthy volunt...